Biochemical control cannot be achieved by the use of somatostatin analogs alone in a large number of patients with acromegaly. Combination therapy with somatostatin analogs and the growth-hormone-receptor antagonist pegvisomant is, however, highly effective at normalizing levels of insulin-like growth factor I. In this Review, the efficacy and safety of somatostatin analog–pegvisomant combination therapy as a potential tool for the medical management of patients with acromegaly is discussed.
- Sebastian J. C. Neggers
- Aart Jan van der Lely
